Landos Biopharma Stock Retained Earnings
| LABPDelisted Stock | USD 4.02 0.15 3.60% |
Landos Biopharma fundamentals help investors to digest information that contributes to Landos Biopharma's financial success or failures. It also enables traders to predict the movement of Landos Stock. The fundamental analysis module provides a way to measure Landos Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Landos Biopharma stock.
Landos |
Landos Biopharma Company Retained Earnings Analysis
Landos Biopharma's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Landos Biopharma Retained Earnings | (155.36 M) |
Most of Landos Biopharma's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Landos Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, Landos Biopharma has a Retained Earnings of (155.36 Million). This is 116.68% lower than that of the Biotechnology sector and 260.34% lower than that of the Health Care industry. The retained earnings for all United States stocks is 101.67% higher than that of the company.
Landos Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Landos Biopharma's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Landos Biopharma could also be used in its relative valuation, which is a method of valuing Landos Biopharma by comparing valuation metrics of similar companies.Landos Biopharma is currently under evaluation in retained earnings category among its peers.
Landos Fundamentals
| Return On Equity | -0.71 | |||
| Return On Asset | -0.39 | |||
| Current Valuation | 42.67 M | |||
| Shares Outstanding | 3.13 M | |||
| Shares Owned By Insiders | 9.88 % | |||
| Shares Owned By Institutions | 52.04 % | |||
| Number Of Shares Shorted | 1.43 K | |||
| Price To Book | 2.11 X | |||
| Price To Sales | 2.37 X | |||
| Gross Profit | 18 M | |||
| EBITDA | (22.73 M) | |||
| Net Income | (21.93 M) | |||
| Cash And Equivalents | 55.75 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 27 K | |||
| Current Ratio | 8.91 X | |||
| Book Value Per Share | 7.43 X | |||
| Cash Flow From Operations | (20.48 M) | |||
| Short Ratio | 0.08 X | |||
| Earnings Per Share | (4.00) X | |||
| Target Price | 12.71 | |||
| Number Of Employees | 19 | |||
| Beta | 0.14 | |||
| Market Capitalization | 71.68 M | |||
| Total Asset | 38.04 M | |||
| Retained Earnings | (155.36 M) | |||
| Working Capital | 31.79 M | |||
| Net Asset | 38.04 M |
About Landos Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Landos Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Landos Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Landos Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Landos Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Landos Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Landos Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Landos Stock
| 0.88 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.71 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.61 | PG | Procter Gamble | PairCorr |
| 0.58 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.43 | AFFL | Affiliated Resources Corp | PairCorr |
The ability to find closely correlated positions to Landos Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Landos Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Landos Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Landos Biopharma to buy it.
The correlation of Landos Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Landos Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Landos Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Landos Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Landos Stock
If you are still planning to invest in Landos Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Landos Biopharma's history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |